Verteporfin

2 papers3 findings

C, W, M, H: cells, worms or flies, mice, humans. Dark: independent labs found the same change there. Light: one lab or one study. Outline: nothing yet.

Labs are independent when their papers share no last author and no institution.

Against: findings that point the other way from most findings on the same outcome.

On aging: the drug’s trials ARN judged to be about aging, of every trial that tests it for any use.

No results posted: trials that ended more than a year ago with no results on ClinicalTrials.gov and no paper in ARN’s record.

Company ties: findings with an author at a company, or from a paper whose competing-interests statement declares ties to one.

2 independent labs in 2 countries

Funders: Agencia Estatal de Investigación and 6 more

Animals2

Outcomes

Abdominal aortic aneurysm

downin mice1

1 study

Verteporfin protects against abdominal aortic aneurysm in mice.
“administration of the YAP signaling inhibitor verteporfin in SM22αCre; Rosa26RFP/+; PGC1αf/f mice restored PVAT function and conferred protection against AAA formation.”
Animalsin SM22αCre; Rosa26RFP/+; PGC1αf/f mice
SM22α-Lineage Perivascular Stromal Cells Contribute to Abdominal Aortic Aneurysm
Circulation research15 May 2025